Table 1.
Clinicopathological factors in this series of autopsy cases
| Patient | Age, years | Sex | MTS (%) | PFS | OS | Pretreatment |
|---|---|---|---|---|---|---|
| 1 | 78 | M | −60.2 | 56 | 84 | Surgery, GEM, S‐1 |
| 2 | 29 | F | −24.4 | 60 | 115 | Surgery, GEM + S‐1, FOLFIRINOX |
| 3 | 48 | M | −37.8 | 58 | 80 | GEM |
| 4 | 63 | M | −112.3 | 55 | 72 | Surgery, GEM, S‐1 |
| 5 | 60 | F | −35.8 | 55 | 145 | S‐1 |
| 6 | 65 | F | NA | 49 | 51 | GEM, GEM + S‐1 |
| 7 | 65 | F | −130.1 | 56 | 76 | Surgery, PBT, S‐1, GEM, FOLFIRINOX, GEM + nabPTX |
| 8 | 61 | F | — | — | — | Surgery, GEM, HIT, GEM + nabPTX, nivolumab |
| 9 | 65 | F | — | — | — | GEM, S‐1 |
| 10 | 71 | M | — | — | — | GEM + S‐1, HIT, S‐1, FOLFIRINOX |
| 11 | 65 | M | — | — | — | FOLFIRINOX, GEM + nabPTX, S‐1 |
| 12 | 76 | F | — | — | — | GEM, GEM + nabPTX |
| 13 | 72 | F | — | — | — | GEM, S‐1, FOLFIRINOX |
Abbreviations: F, female; FOLFIRINOX, leucovorin + fluorouracil + irinotecan + oxaliplatin; GEM, gemcitabine; HIT, heavy ion radiotherapy; M, male; MTS, maximum tumor shrinkage; nabPTX, nanoparticle albumin‐bound paclitaxel; OS, overall survival; PBT, proton beam therapy; PFS, progression‐free survival; S‐1, tegafur/gimeracil/oteracil potassium.